Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro
- 402 Downloads
Conventional anticancer chemotherapy is limited because of severe side effects as well as a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have explored a C60 fullerene-based nanosized system as a carrier for anticancer drugs for an optimized drug delivery to leukemic cells.
Here, we studied the physicochemical properties and anticancer activity of C60 fullerene noncovalent complexes with the commonly used anticancer drug doxorubicin. C60-Doxorubicin complexes in a ratio 1:1 and 2:1 were characterized with UV/Vis spectrometry, dynamic light scattering, and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The obtained analytical data indicated that the 140-nm complexes were stable and could be used for biological applications. In leukemic cell lines (CCRF-CEM, Jurkat, THP1 and Molt-16), the nanocomplexes revealed ≤ 3.5 higher cytotoxic potential in comparison with the free drug in a range of nanomolar concentrations. Also, the intracellular drug’s level evidenced C60 fullerene considerable nanocarrier function.
The results of this study indicated that C60 fullerene-based delivery nanocomplexes had a potential value for optimization of doxorubicin efficiency against leukemic cells.
KeywordsC60 fullerene Doxorubicin Noncovalent complex Leukemic cells Cytotoxicity Accumulation
Fetal bovine serum
High-performance liquid chromatography-tandem mass spectrometry
Half-maximal inhibitory concentration
Limit of detection
Limit of quantification
Multiple reactions monitoring
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
The main efforts in cancer research aim at finding more powerful and selective ways for direct elimination of cancer cells. This task can be addressed with means of nanobiotechnology. Recent progress in this field has arisen interest in a carbon nanostructure — C60 fullerene  that not only exhibits unique physicochemical properties [2, 3], biological activity [4, 5, 6, 7, 8, 9, 10] and antioxidant behavior [11, 12, 13, 14], but also possesses a significant potential to serve as a nanocarrier for drug delivery into cancer cells [15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25] (here consistently abbreviated as “C60”).
The anticancer anthracycline chemotherapeutic drug Doxorubicin (here abbreviated consistently as “Dox”) is one of the first candidates for a more targeted nanodelivery due to life-threatening cardiotoxicity and other serious side effects [25, 26]. The main mechanism of Dox toxicity against cancer cells is its intercalation into nuclear DNA followed by inhibition of topoisomerase activity, DNA replication, and repair [26, 27, 28]. But Dox’s side effects on cardiomyocytes are considered to be determined by another mechanism, mainly, iron-related reactive oxygen species formation [27, 28]. The combination of C60 antioxidant potential [2, 11, 13] and its ability for drug delivery [24, 25] makes the nanostructure very attractive for anticancer therapy.
Complexation of Dox with nanostructures increases the drug’s size, both improving its retention in the organism and prolonging the therapeutic activity [29, 30]. To develop an applicable nanosystem for a successful anticancer drug delivery, previous studies focused on aspects regarding stability, biocompatibility, biodistribution and functionality [29, 30, 31, 32, 33].
A coupling of Dox and C60 for a passive targeting of cancer cells can be achieved by covalent linkage [15, 16, 17, 23] or by noncovalent interactions [18, 19, 20, 21, 22]. A complex of C60 with two amide-linked Dox molecules showed the same cytotoxicity against human breast cancer MCF-7 cells as the free drug . When Dox was bound to C60 through a carbamate linker, it exhibited no change in antitumor efficacy but had no systemic toxicity in a murine tumor model . When one or two Dox molecules were anchored on pegylated C60 particles through a urethane type bond, the complex exhibited even a delayed antiproliferative effect on MCF-7 cells .
For noncovalent complexation of the aromatic Dox molecule with the polyaromatic surface of C60, the π-π stacking effect is responsible. In a pioneering attempt, Evstigneev et al.  showed a simple and fast method of C60 noncovalent complexation with Dox in water  and in physiological solution . The proposed nanosystem was shown to have higher toxicity compared with the free drug against various human tumor cell lines in vitro and mice Lewis lung carcinoma in vivo [21, 22]. In another approach, an antimicrobial effect and the applicability for in vivo imaging were shown .
The aim of the presented research is to assess the physicochemical properties of the C60-Dox complex formed after noncovalent interaction of the components, its intracellular accumulation and сytotoxic potential against human leukemic cells lines.
RPMI 1640 liquid medium, phosphate-buffered saline (PBS), fetal bovine serum (FBS), penicillin/streptomycin and L-glutamin were obtained from Biochrom (Berlin, Germany). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and Hoechst 33342 were obtained from Sigma-Aldrich Co. (St-Louis, USA). Dimethylsulfoxide (DMSO), sodium chloride, acetonitrile, formic acid and trypan blue from Carl Roth GmbH + Co. KG (Karlsruhe, Germany) were used.
C60 and C60-Dox Complex Synthesis
The pristine C60 aqueous colloid solution was prepared by C60 transfer from toluene to water using continuous ultrasound sonication as described by Ritter et al.  The obtained C60 water colloid solution had a final concentration of 150 μg/ml with 99% purity, stability and homogeneity and an average nanoparticle’s size of 100 nm [34, 35].
Dox (“Doxorubicin-TEVA”, Pharmachemie B.V., Utrecht, Netherlands) was dissolved in physiological solution at an initial concentration of 150 μg/ml.
A C60-Dox complex was prepared according to the protocol . Briefly, C60 and Dox solutions were mixed in 1:1 or 2:1 weight ratio. The mixture was treated in the ultrasonic disperser for 30 min and stirred magnetically for 24 h at room temperature. The final concentration of both C60 and Dox in the C60-Dox 1:1 complex was 75 μg/ml. The final concentration of C60 and Dox in the C60-Dox 2:1 complex was 100 μg/ml and 50 μg/ml, respectively. The unbound drug was washed out with the Pur-A-LyzerTM Midi 1000 Dialysis Kit Sigma-Aldrich Co. (St. Louis, USA). The stability (ζ-potential value) and size distribution (hydrodynamic diameter) [20, 36, 37, 38, 39] of complexes were systematically checked and shown to be practically unchanged after 6 months of storage in physiological saline solution. The working concentration of C60-Dox complexes in the probes was presented according to Dox-equivalent concentration in the range of 0.1–100 μM purposely to compare the effect of the complexes with the effect of free drug in the same concentration.
High-Performance Liquid Chromatography-Tandem Mass Spectrometry
HPLC-ESI-MS/MS conditions for analysis of Dox
Agilent Eclipse XDB-C18
Acetonitrile, 0.1% formic acid in H2O (80:20, v:v)
• Desolvation line temperature
• Heat block temperature
Target molecular ion
544.2 [M]+ m/z
130.2, 361.1 m/z
Nebulizing gas flow
Drying gas flow
For data processing, the software LabSolutions HPLC-MS/MS (Shimadzu, Kyoto, Japan) was used. Other parameters were tuned automatically.
Dox calibration standards from 0.005 to 5 μM were prepared from a 1.85 mM water stock solution. The standards were stored in the dark at 4 °C. The calibration curves were plotted with 1/X weighting, r2 = 0.99463. The limits of detection (LOD) and quantification (LOQ) were defined according to LOD = 3.3 × s/Slope and LOQ = 10 × s/Slope, respectively, where s is the standard deviation of the regression line.
Spectroscopic and Fluorometric Analysis
The absorbance and fluorescence spectra of the free Dox and C60-Dox complex were measured at the following parameters: (1) absorbance — wavelength range 400–550 nm, wavelength step size 5 nm, number of flashes per well 25; (2) fluorescence — λex = 470 nm, wavelength range 500–800 nm, wavelength step size 2 nm, number of flashes per well 25. A volume of 100 μl of the studied solutions was measured in the 96-well plates Sarstedt (Nümbrecht, Germany) with a multimode microplate spectrometer Tecan Infinite M200 Pro (Männedorf, Switzerland).
Dynamic Light Scattering
C60-Dox complex size distribution was evaluated with a Zetasizer Nano S (Malvern Instruments, UK) equipped with a He-Ne laser (633 nm). Data were recorded at 37 °C in backscattering modus at a scattering angle of 2θ = 173°.
The human cancer T-cell lines of leucosis origin CCRF-CEM (ACC 240), Jurkat (ACC 282), and Molt-16 (ACC 29) were purchased from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen und Zellkulturen). The THP1 was kindly provided by Dr. Sofia Cortes (New University of Lisbon, Portugal).
Cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 2 mM glutamine, using 25 cm2 flasks at a 37 °C with 5% CO2 in a humidified incubator Binder (Tuttlingen, Germany). The number of viable cells was counted upon 0.1% trypan blue staining with a Roche Cedex XS Analyzer (Basel, Switzerland).
104cells/well were cultured in 96-well cell culture plates Sarstedt (Nümbrecht, Germany) for 24 h. The cell culture medium was replaced by a drug-supplemented medium. Cells were incubated in the presence of varying concentrations of free Dox or C60-Dox complex. After 24, 48, and 72 h of incubation, cell viability was determined with the MTT reduction assay . Briefly, 10 μl of MTT solution (5 mg/ml in PBS) was added to each well and cells were incubated for 2 h at 37 °C. The culture medium was then replaced with 100 μl of DMSO, and diformazan formation was determined by measuring absorption at λ = 570 nm with the microplate reader Tecan Infinite M200 Pro (Männedorf, Switzerland). Curve fitting and calculation of the half-maximal inhibitory concentration (IC50) values were done using specialized software GraphPad Prism 7 (GraphPad Software Inc., USA). Briefly, individual concentration-effect curves were generated by fitting the logarithm of the tested compound concentration versus corresponding normalized percent of cell viability values using nonlinear regression.
CCRF-CEM cells were seeded in 6-well plates Sarstedt (Nümbrecht, Germany) at a cell density of 2 × 105 cells/well in 2 ml of culture medium and incubated for 24 h. Then, cells were treated with 1 μM free Dox or C60-Dox complex during 1, 3, and 6 h and washed with PBS. Visualization was performed with a Fluorescence Microscope Keyence BZ-9000 BIOREVO (Osaka, Japan) equipped with red (λex = 480 nm, λem = 600 nm) filter and a respective acquisition software Keyence BZ-II Viewer (Osaka, Japan).
CCRF-CEM cells (2 × 105/well, 2 ml) were seeded in 6-well plates, incubated for 24 h, and then treated with 1 μM free and C60 bound Dox. After 1, 3, and 6 h incubation, the cells were harvested, washed with PBS, and analyzed with the flow cytometer BD FACSJazz™ (Singapore). A minimum of 2 × 104 cells per sample were acquired and analyzed with the BD FACS™ software (Singapore).
All experiments were carried out with a minimum of four replicates. Data analysis was performed with the use of the GraphPad Prism 7 (GraphPad Software Inc., USA). Paired Student’s t tests were performed. Difference values p < 0.05 were considered to be significant.
Results and Discussion
HPLC-MS/MS Analysis of C60-Dox Complexes
For chromatographic separation we used the reverse-phase conditions expecting that during the separation process, hydrophobic C60 molecules are retained on the column much stronger than those of the more polar Dox . Elution with the polar mobile phase should evidently cause decomposition of the complex and release of free Dox that possesses higher affinity to mobile phase and can be detected by mass spectrometry.
Spectroscopic and Fluorometric Analysis
The long wavelength absorption maximum of Dox (λ = 480 nm) was used as an excitation wavelength for tracking its fluorescence. The fluorescence spectrum exhibits one broad band that consists of three peaks at 560, 594 and 638 nm with a maximum around 594 nm (Fig. 2b) , whereas C60 has no detectable fluorescence at this spectral band. C60-Dox complexes’ fluorescence was estimated in a series of dilutions with Dox-equivalent concentration from 3 to 50 μM. Regardless of dilution, the fluorescence of Dox (λex = 480 nm, λem = 594 nm) in the complexes was quenched by C60 moieties (Fig. 2b). Thus, the fluorescence of Dox in both complexes at 3 μM Dox-equivalent concentration appeared to be quenched by 50%. The observed Dox fluorescence quenching is attributed to the strong electron-accepting capability of C60  and intramolecular excited-state energy transfer typical for noncovalent Dox complexes [18, 36, 45], indicating on the close spatial proximity of the components.
Size Distribution Analysis by Dynamic Light Scattering
The dynamic light scattering data on 1 μM C60-Dox 1:1 and 2:1 nanocomplex’s hydrodynamic diameter distribution in FBS-supplemented cell culture showed that their size was 138 ± 6 nm and 139 ± 5 nm when measured immediately (Fig. 3a) and 146 ± 4 nm and 144 ± 5 nm after 72 h of incubation (Fig. 3b), respectively.
The detected stability of the maximum (around 140 nm) indicated that there was no additional aggregation of the C60-Dox complexes during a prolonged incubation in FBS-supplemented cell culture medium which confirmed their suitability for in vitro studies.
Viability of human leukemic cells of different lines was estimated by MTT test at 24, 48, and 72 h of incubation in the presence of C60-Dox complexes as well as of free Dox separately at equivalent concentrations. C60 alone at concentrations equivalent to those in the complexes had no effect on leukemic cells viability (data not shown).
Under action of 100 nM Dox, the viability of CCRF-CEM cells was decreased to 84 ± 7, 50 ± 4 and 34 ± 7% compared to the control at 24, 48 and 72 h, respectively. The comparable pattern of 100 nM Dox toxic effect was found in Jurkat cells. The viability of THP1 cells after treatment with 100 nM Dox cells was found to be 50 ± 4, 47 ± 5, and 13 ± 4% at 24, 48 and 72 h, respectively. Half-maximal inhibitory Dox concentrations (IC50) for CCRF-CEM, THP1 and Jurkat cells at 72 h of incubation were estimated to be 80 ± 9, 43 ± 5 and 38 ± 6 nM, respectively. These data correspond to literature data [48, 49]. Molt-16 cells appeared to be the most sensitive to the drug since its toxic effect was detected in the range from 1 to 25 nM within all periods of cell incubation. The viability of Molt-16 cells treated with 5 nM Dox was decreased to 75 ± 4, 28 ± 4 and 18 ± 4% of that of control at 24, 48 and 72 h, respectively, and the value of IC50 at 72 h was equal to only 2.0 nM. The similar high sensitivity of Molt-16 cells with 10 times more intensive apoptosis induction in comparison with Jurkat cells under treatment of a herbal alkaloid was previously reported by Cai et al. .
Cells treated with free Dox were used as a control to assess the viability under action of C60-Dox complexes at the equivalent doses of the drug. The value of IC50 for the free Dox and C60-Dox complexes was calculated for each time point and cell line and is listed in Fig. 4.
It was shown that both C60-Dox complexes possessed higher toxic potential compared to the free Dox against human leukemic cell lines (Fig. 4).
In summary, our numerous experiments showed for the four cell lines a variety of enhanced toxicities up to 3.5-fold. C60-Dox 1:1 complex has shown higher toxicity in comparison with 2:1 complex. The less pronounced effect (IC50 decrease on ≥ 2.5 times compared with that for free Dox) of the 2:1 complex can be attributed to the higher concentration of C60 as its component. Due to its antioxidant activity [11, 13], excess of C60 can protect cells against Dox-associated oxidative stress .
Intracellular Accumulation of Free Dox and C60-Dox Complexes
Mean fluorescence intensity (FI) of intracellular accumulated Dox estimated by FACS histograms
45 ± 7
85 ± 9
107 ± 11
68 ± 9*
145 ± 12*
236 ± 22*
57 ± 8*
131 ± 21*
234 ± 23*
Time-dependent accumulation of 1 μM Dox was estimated by fluorescence intensity enhancement (Fig. 5, Table 2). The fluorescence microscopy images illustrate that C60-Dox complexes were internalized faster than free drug as evidenced by much brighter intracellular fluorescence (Fig. 5b). The mean fluorescent intensities of the CCRF-CEM cells, treated with 1:1 C60-Dox complex at 1 μM Dox-equivalent concentration, were increased in 1.5, 1.7 and 2.2 times compared to free Dox at 1, 3 and 6 h, respectively. 2:1 C60-Dox complex exhibited delayed intracellular drug accumulation reaching the same level as 1:1 complex at 6 h (Fig. 5, Table 2).
The obtained data demonstrated that Dox complexation with C60 promoted the entry into the cells but did not affect its localization. The control staining of studied cells with DNA binding dye Hoechst 33342 revealed its colocalization with Dox signal (data not shown). Evidently, Dox molecules from C60 complexes and the free drug entered the nuclei that reflect its antiproliferative impact through DNA damage [26, 27, 28]. An increased drug’s intracellular uptake upon complexation with C60 points towards the latter functioning as a drug transport promoter. C60 nanostructure was shown to transmigrate the cellular plasma membrane due to passive diffusion  and/or endocytosis/pinocytosis [52, 53], whereas such small molecules as Dox can penetrate only via passive diffusion. The C60 structure resembles the structure of clathrine [54, 55], the major coat component of vesicle formation during endocytosis. Therefore, C60 may function as a transporter of small aromatic molecules . On the contrary, a covalent bond between carrier and cargo introduces a structural alteration into the drug molecule. Consequently, the accumulation pattern and interaction with intracellular targets are altered resulting in complete or partial loss of the drug’s function. Liu et al.  showed that C60 with two Dox molecules bound through an amide bond was distributed predominantly in the cytoplasm.
The physicochemical properties of C60-Dox complexes with 1:1 and 2:1 ratio of the components were determined, and their toxicity against human leukemic cells CCRF-CEM, Jurkat, Molt-16 and THP1 was estimated.
HPLC-MS/MS analysis revealed evident distinctions in chromatograms of free Dox and those released from C60-Dox complexes. Complexation of C60 with Dox was confirmed by absorption hypochromic effect and fluorescence quenching in C60-Dox complexes. We determined that the size of C60-Dox complexes around 140 nm was retained in the presence of protein and prolonged incubation in the medium. Studies on human leukemic cell lines revealed that C60-Dox complexes possessed higher cytotoxicity compared to the free drug in equivalent concentrations. At 72 h of incubation of cells, the value of IC50 for 1:1 and 2:1 complexes was decreased on ≤ 3.5 and ≤ 2.5 times, respectively, in comparison with IC50 for the free drug. Complexation with C60 promoted Dox entry into leukemic cells. A treatment of CCRF-CEM cells for 6 h with C60-Dox complexes in 1 μM Dox-equivalent concentration was followed by 2.2-fold increase of drug intracellular level as compared to treatment with free Dox.
Our results confirm the function of C60 as a nanocarrier and the perspective of its application for optimization of Dox efficiency against leukemic cells. As Dox is only a representative or model substance for many antitumor drugs, we expect that our findings may be transferred to other drugs. Increasing a drug’s uptake into tumor cells and/or its antitumor qualities may point towards new treatment strategies. Complexation of drugs with nanocarriers may serve to reduce their efficacious dose rates and thus attenuate the unwanted side effects.
The authors are grateful to Eckhart Kornejew (Technical University of Applied Sciences Wildau) for his support of dynamic light scattering measurements. AG thanks Dr. Lars Radke and Desiree Grienitz (Technical University of Applied Sciences Wildau) for their help in cell culture and flow cytometry.
The authors thank the German Academic Exchange Service (DAAD) for their support (scholarship for AG 57129429). TD acknowledges support by BMBF (Remis-3R, FKZ 031L0129B).
Availability of Data and Materials
The datasets generated and analysed during the current study are included in this published article.
The presented work was carried out in collaboration between all authors. MF, TD, YP, and OM coordinated the research work. SP, YP, and UR synthesized and characterized C60 and C60-Dox nanomaterials. SG carried out the HPLC-MS/MS analysis. AG performed spectrophotometry, dynamic light scattering, cell-based assays, and the statistical analysis. AG, OM, and MF analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 9.Huang L, Bhayana B, Xuan W et al (2018) Comparison of two functionalized fullerenes for antimicrobial photodynamic inactivation: potentiation by potassium iodide and photochemical mechanisms. J Photochem Photobiol B Biol 186:197–206. https://doi.org/10.1016/j.jphotobiol.2018.07.027 CrossRefGoogle Scholar
- 31.Pillai G (2014) Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci 13 https://doi.org/10.15226/2374-6866/1/2/00109
- 40.Carmichael J, DeGraff WG, Gazdar AF et al (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942Google Scholar
- 44.Grebinyk A, Grebinyk S, Prylutska S et al (2018) C60 fullerene accumulation in human leukemic cells and perspectives of LED-mediated photodynamic therapy. Free Radic Biol Med 124:319–327. https://doi.org/10.1016/j.freeradbiomed.2018.06.022 CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.